Skip to main content

Biogen Inc. (BIIB) Stock Analysis

Breakout setup

Buy WaitModerate Confidence

Healthcare · Drug Manufacturers - General

Wait for pullback to $171.57. At $188.07 the A.R:R is 0.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $171.57 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: TYSABRI and SPINRAZA; Analyst target reached - limited upside remaining.

Biogen is a global biopharma focused on neurology (MS, Alzheimer's, ALS) and rare diseases (SMA, Friedreich's ataxia). Key marketed products include TYSABRI, SPINRAZA, SKYCLARYS, and QALSODY; LEQEMBI for Alzheimer's is co-commercialized with Eisai. TYSABRI and SPINRAZA each... Read more

$188.07+11.4% A.UpsideScore 6.1/10#3 of 16 Drug Manufacturers - General
Entry $171.57(Support Atr Sticky)Stop $159.66Target $191.26(analyst − 10%)A.R:R 0.2:1Setup A.R:R 2.4:1
Analyst target$212.51+13.0%29 analysts
$191.26our TP
$188.07price
$212.51mean
$150
$275

Wait for pullback to $171.57. At $188.07 the A.R:R is 0.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $171.57 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: TYSABRI and SPINRAZA; Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Score 6.1/10, moderate confidence.

Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 90d clear, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.

Val6.3Qual7.0Grw5.6Mom6.8Sent7.0Ins5.2Peer4.0Tech4.7Risk6.56.1OVERALL

Thesis

Rewards
Strong earnings beat streak (4/4)
Positive news sentiment (+0.97)
High-quality business
Risks
Concentration risk — Product: TYSABRI and SPINRAZA
Analyst target reached - limited upside remaining

Key Metrics

P/E (TTM)20.4
P/E (Fwd)11.9
Mkt Cap$27.9B
EV/EBITDA8.6
Profit Mgn13.8%
ROE7.7%
Rev Growth1.9%
Beta0.16
DividendNone
Rating analysts43

Quality Signals

Piotroski F9/9

Options Flow

P/C1.38bearish
IV43%normal
Max Pain$95-49.5% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductTYSABRI and SPINRAZA
    10-K Item 1: 'Product sales for TYSABRI and SPINRAZA each accounted for more than 10.0% of our total revenue for the years ended December 31, 2025, 2024 and 2023'

Material Events(8-K, last 90d)

  • 2026-03-11Item 5.02MEDIUM
    Susan H. Alexander, Chief Legal Officer, will depart Biogen effective end of May 2026. The Company has initiated a search for the next Chief Legal Officer. No successor named at time of filing.
    SEC filing →
  • 2026-02-11Item 5.02LOW
    Caroline Dorsa (Board Chair) announced she will not stand for re-election at the 2026 annual meeting. Decision not related to any disagreement. Dr. Maria C. Friere elected as Chair effective after the annual meeting.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

10 dimensions · all in-band

GatesA.R:R 0.2 < 1.5@spotMomentum 6.8>=5.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 90d clearSEMI CYCLE PEAK CLEARBreakoutSuitability: Moderate
RSI
61 · Neutral
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $168.64Resistance $195.98

Price Targets

$160
$172
$191
A.Upside+1.7%
A.R:R0.2:1
Setup A.R:R (at entry)2.4:1

Position Sizing

ConvictionMedium conviction
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (1.8% upside)
! NEWS_MOD=+2: HOLD_IF_HOLDING → STRONG_BUY_WAIT
! Reward/Risk 0.2:1 at current price — below 1.5:1 minimum

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-07-30 (90d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is BIIB stock a buy right now?

Wait for pullback to $171.57. At $188.07 the A.R:R is 0.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $171.57 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: TYSABRI and SPINRAZA; Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Target $191.26 (+1.7%), stop $159.66 (−17.8%), Setup A.R:R 2.4:1. Score 6.1/10, moderate confidence.

What is the BIIB stock price target?

Take-profit target: $191.26 (+11.4% upside). Target $191.26 (+1.7%), stop $159.66 (−17.8%), Setup A.R:R 2.4:1. Stop-loss: $159.66.

What are the risks of investing in BIIB?

Concentration risk — Product: TYSABRI and SPINRAZA; Analyst target reached - limited upside remaining.

Is BIIB overvalued or undervalued?

Biogen Inc. trades at a P/E of 20.4 (forward 11.9). TrendMatrix value score: 6.3/10. Verdict: Buy (Wait for Entry).

What do analysts say about BIIB?

43 analysts cover BIIB with a consensus score of 3.7/5. Average price target: $213.

What does Biogen Inc. do?Biogen is a global biopharma focused on neurology (MS, Alzheimer's, ALS) and rare diseases (SMA, Friedreich's ataxia)....

Biogen is a global biopharma focused on neurology (MS, Alzheimer's, ALS) and rare diseases (SMA, Friedreich's ataxia). Key marketed products include TYSABRI, SPINRAZA, SKYCLARYS, and QALSODY; LEQEMBI for Alzheimer's is co-commercialized with Eisai. TYSABRI and SPINRAZA each exceeded 10% of total 2025 revenue.

Related stocks: GILD (Gilead Sciences, Inc.) · GSK (GSK plc) · AMGN (Amgen Inc.) · GRFS (Grifols, S.A.) · MRK (Merck & Company, Inc.)